Triple-negative versus non-triple-negative breast cancers in high-risk women: Phenotype features and survival from the HIBCRIT-1 MRI-including screening study

Franca Podo, Filippo Santoro, Giovanni Di Leo, Siranoush Manoukian, Clelia de Giacomi, Stefano Corcione, Laura Cortesi, Luca A. Carbonaro, Rubina M. Trimboli, A. Cilotti, Lorenzo Preda, Bernardo Bonanni, M. Pensabene, Laura Martincich, Antonella Savarese, A. Contegiacomo, Francesco Sardanelli

Research output: Contribution to journalArticle

Abstract

Purpose: To compare phenotype features and survival of triple-negative breast cancers (TNBC) versus non-TNBCs detected during a multimodal annual screening of high-risk women. Experimental Design: Analysis of data from asymptomatic high-risk women diagnosed with invasive breast cancer during the HIBCRIT-1 study with median 9.7-year follow-up. Results: Of 501 enrolled women with BRCA1/2 mutation or strong family history (SFH), 44 were diagnosed with invasive breast cancers: 20 BRCA1 (45%), 9 BRCA2 (21%), 15 SFH (34%). Magnetic resonance imaging (MRI) sensitivity (90%) outperformed that of mammography (43%, P <0.001) and ultrasonography (61%, P = 0.004). The 44 cases (41 screen-detected; 3 BRCA1-associated interval TNBCs) comprised 14 TNBCs (32%) and 30 non-TNBCs (68%), without significant differences for age at diagnosis, menopausal status, prophylactic oophorectomy, or previous breast cancer. Of 14 TNBC patients, 11 (79%) were BRCA1; of the 20 BRCA1 patients, 11 (55%) had TNBC; and of 15 SFH patients, 14 (93%) had non-TNBCs (P = 0.007). Invasive ductal carcinomas (IDC) were 86% for TNBCs versus 43% for non-TNBCs (P = 0.010), G3 IDCs 71% versus 23% (P = 0.006), size 16±5mmversus 12±6mm(P=0.007). TNBC patients had more frequent ipsilateral mastectomy (79% vs. 43% for non- TNBCs, P = 0.050), contralateral prophylactic mastectomy (43% vs. 10%, P=0.019), and adjuvant chemotherapy (100% vs. 44%, P <0.001). The 5-year overall survival was 86% ± 9% for TNBCs versus 93% ± 5% (P = 0.946) for non-TNBCs; 5-year disease-free survival was 77% ± 12% versus 76% ± 8% (P = 0.216). Conclusions: In high-risk women, by combining an MRIincluding annual screening with adequate treatment, the usual reported gap in outcome between TNBCs and non-TNBCs could be reduced..

Original languageEnglish
Pages (from-to)895-904
Number of pages10
JournalClinical Cancer Research
Volume22
Issue number4
DOIs
Publication statusPublished - Feb 15 2016

Fingerprint

Triple Negative Breast Neoplasms
Magnetic Resonance Imaging
Breast Neoplasms
Phenotype
Survival
Ductal Carcinoma
Mastectomy
Ovariectomy
Mammography
Adjuvant Chemotherapy
Disease-Free Survival
Ultrasonography
Research Design
Mutation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Triple-negative versus non-triple-negative breast cancers in high-risk women : Phenotype features and survival from the HIBCRIT-1 MRI-including screening study. / Podo, Franca; Santoro, Filippo; Di Leo, Giovanni; Manoukian, Siranoush; de Giacomi, Clelia; Corcione, Stefano; Cortesi, Laura; Carbonaro, Luca A.; Trimboli, Rubina M.; Cilotti, A.; Preda, Lorenzo; Bonanni, Bernardo; Pensabene, M.; Martincich, Laura; Savarese, Antonella; Contegiacomo, A.; Sardanelli, Francesco.

In: Clinical Cancer Research, Vol. 22, No. 4, 15.02.2016, p. 895-904.

Research output: Contribution to journalArticle

Podo, Franca ; Santoro, Filippo ; Di Leo, Giovanni ; Manoukian, Siranoush ; de Giacomi, Clelia ; Corcione, Stefano ; Cortesi, Laura ; Carbonaro, Luca A. ; Trimboli, Rubina M. ; Cilotti, A. ; Preda, Lorenzo ; Bonanni, Bernardo ; Pensabene, M. ; Martincich, Laura ; Savarese, Antonella ; Contegiacomo, A. ; Sardanelli, Francesco. / Triple-negative versus non-triple-negative breast cancers in high-risk women : Phenotype features and survival from the HIBCRIT-1 MRI-including screening study. In: Clinical Cancer Research. 2016 ; Vol. 22, No. 4. pp. 895-904.
@article{9c32a633bbe941d38ac8f548e38acd3e,
title = "Triple-negative versus non-triple-negative breast cancers in high-risk women: Phenotype features and survival from the HIBCRIT-1 MRI-including screening study",
abstract = "Purpose: To compare phenotype features and survival of triple-negative breast cancers (TNBC) versus non-TNBCs detected during a multimodal annual screening of high-risk women. Experimental Design: Analysis of data from asymptomatic high-risk women diagnosed with invasive breast cancer during the HIBCRIT-1 study with median 9.7-year follow-up. Results: Of 501 enrolled women with BRCA1/2 mutation or strong family history (SFH), 44 were diagnosed with invasive breast cancers: 20 BRCA1 (45{\%}), 9 BRCA2 (21{\%}), 15 SFH (34{\%}). Magnetic resonance imaging (MRI) sensitivity (90{\%}) outperformed that of mammography (43{\%}, P <0.001) and ultrasonography (61{\%}, P = 0.004). The 44 cases (41 screen-detected; 3 BRCA1-associated interval TNBCs) comprised 14 TNBCs (32{\%}) and 30 non-TNBCs (68{\%}), without significant differences for age at diagnosis, menopausal status, prophylactic oophorectomy, or previous breast cancer. Of 14 TNBC patients, 11 (79{\%}) were BRCA1; of the 20 BRCA1 patients, 11 (55{\%}) had TNBC; and of 15 SFH patients, 14 (93{\%}) had non-TNBCs (P = 0.007). Invasive ductal carcinomas (IDC) were 86{\%} for TNBCs versus 43{\%} for non-TNBCs (P = 0.010), G3 IDCs 71{\%} versus 23{\%} (P = 0.006), size 16±5mmversus 12±6mm(P=0.007). TNBC patients had more frequent ipsilateral mastectomy (79{\%} vs. 43{\%} for non- TNBCs, P = 0.050), contralateral prophylactic mastectomy (43{\%} vs. 10{\%}, P=0.019), and adjuvant chemotherapy (100{\%} vs. 44{\%}, P <0.001). The 5-year overall survival was 86{\%} ± 9{\%} for TNBCs versus 93{\%} ± 5{\%} (P = 0.946) for non-TNBCs; 5-year disease-free survival was 77{\%} ± 12{\%} versus 76{\%} ± 8{\%} (P = 0.216). Conclusions: In high-risk women, by combining an MRIincluding annual screening with adequate treatment, the usual reported gap in outcome between TNBCs and non-TNBCs could be reduced..",
author = "Franca Podo and Filippo Santoro and {Di Leo}, Giovanni and Siranoush Manoukian and {de Giacomi}, Clelia and Stefano Corcione and Laura Cortesi and Carbonaro, {Luca A.} and Trimboli, {Rubina M.} and A. Cilotti and Lorenzo Preda and Bernardo Bonanni and M. Pensabene and Laura Martincich and Antonella Savarese and A. Contegiacomo and Francesco Sardanelli",
year = "2016",
month = "2",
day = "15",
doi = "10.1158/1078-0432.CCR-15-0459",
language = "English",
volume = "22",
pages = "895--904",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Triple-negative versus non-triple-negative breast cancers in high-risk women

T2 - Phenotype features and survival from the HIBCRIT-1 MRI-including screening study

AU - Podo, Franca

AU - Santoro, Filippo

AU - Di Leo, Giovanni

AU - Manoukian, Siranoush

AU - de Giacomi, Clelia

AU - Corcione, Stefano

AU - Cortesi, Laura

AU - Carbonaro, Luca A.

AU - Trimboli, Rubina M.

AU - Cilotti, A.

AU - Preda, Lorenzo

AU - Bonanni, Bernardo

AU - Pensabene, M.

AU - Martincich, Laura

AU - Savarese, Antonella

AU - Contegiacomo, A.

AU - Sardanelli, Francesco

PY - 2016/2/15

Y1 - 2016/2/15

N2 - Purpose: To compare phenotype features and survival of triple-negative breast cancers (TNBC) versus non-TNBCs detected during a multimodal annual screening of high-risk women. Experimental Design: Analysis of data from asymptomatic high-risk women diagnosed with invasive breast cancer during the HIBCRIT-1 study with median 9.7-year follow-up. Results: Of 501 enrolled women with BRCA1/2 mutation or strong family history (SFH), 44 were diagnosed with invasive breast cancers: 20 BRCA1 (45%), 9 BRCA2 (21%), 15 SFH (34%). Magnetic resonance imaging (MRI) sensitivity (90%) outperformed that of mammography (43%, P <0.001) and ultrasonography (61%, P = 0.004). The 44 cases (41 screen-detected; 3 BRCA1-associated interval TNBCs) comprised 14 TNBCs (32%) and 30 non-TNBCs (68%), without significant differences for age at diagnosis, menopausal status, prophylactic oophorectomy, or previous breast cancer. Of 14 TNBC patients, 11 (79%) were BRCA1; of the 20 BRCA1 patients, 11 (55%) had TNBC; and of 15 SFH patients, 14 (93%) had non-TNBCs (P = 0.007). Invasive ductal carcinomas (IDC) were 86% for TNBCs versus 43% for non-TNBCs (P = 0.010), G3 IDCs 71% versus 23% (P = 0.006), size 16±5mmversus 12±6mm(P=0.007). TNBC patients had more frequent ipsilateral mastectomy (79% vs. 43% for non- TNBCs, P = 0.050), contralateral prophylactic mastectomy (43% vs. 10%, P=0.019), and adjuvant chemotherapy (100% vs. 44%, P <0.001). The 5-year overall survival was 86% ± 9% for TNBCs versus 93% ± 5% (P = 0.946) for non-TNBCs; 5-year disease-free survival was 77% ± 12% versus 76% ± 8% (P = 0.216). Conclusions: In high-risk women, by combining an MRIincluding annual screening with adequate treatment, the usual reported gap in outcome between TNBCs and non-TNBCs could be reduced..

AB - Purpose: To compare phenotype features and survival of triple-negative breast cancers (TNBC) versus non-TNBCs detected during a multimodal annual screening of high-risk women. Experimental Design: Analysis of data from asymptomatic high-risk women diagnosed with invasive breast cancer during the HIBCRIT-1 study with median 9.7-year follow-up. Results: Of 501 enrolled women with BRCA1/2 mutation or strong family history (SFH), 44 were diagnosed with invasive breast cancers: 20 BRCA1 (45%), 9 BRCA2 (21%), 15 SFH (34%). Magnetic resonance imaging (MRI) sensitivity (90%) outperformed that of mammography (43%, P <0.001) and ultrasonography (61%, P = 0.004). The 44 cases (41 screen-detected; 3 BRCA1-associated interval TNBCs) comprised 14 TNBCs (32%) and 30 non-TNBCs (68%), without significant differences for age at diagnosis, menopausal status, prophylactic oophorectomy, or previous breast cancer. Of 14 TNBC patients, 11 (79%) were BRCA1; of the 20 BRCA1 patients, 11 (55%) had TNBC; and of 15 SFH patients, 14 (93%) had non-TNBCs (P = 0.007). Invasive ductal carcinomas (IDC) were 86% for TNBCs versus 43% for non-TNBCs (P = 0.010), G3 IDCs 71% versus 23% (P = 0.006), size 16±5mmversus 12±6mm(P=0.007). TNBC patients had more frequent ipsilateral mastectomy (79% vs. 43% for non- TNBCs, P = 0.050), contralateral prophylactic mastectomy (43% vs. 10%, P=0.019), and adjuvant chemotherapy (100% vs. 44%, P <0.001). The 5-year overall survival was 86% ± 9% for TNBCs versus 93% ± 5% (P = 0.946) for non-TNBCs; 5-year disease-free survival was 77% ± 12% versus 76% ± 8% (P = 0.216). Conclusions: In high-risk women, by combining an MRIincluding annual screening with adequate treatment, the usual reported gap in outcome between TNBCs and non-TNBCs could be reduced..

UR - http://www.scopus.com/inward/record.url?scp=84964253698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964253698&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-15-0459

DO - 10.1158/1078-0432.CCR-15-0459

M3 - Article

VL - 22

SP - 895

EP - 904

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 4

ER -